# Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)

> **NCT01370642** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 294 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** vaniprevir
- **DRUG:** Placebo to vaniprevir
- **BIOLOGICAL:** Peg-IFN
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01370642
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-27
- **Primary completion:** 2013-07-31
- **Final completion:** 2014-03-17
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01370642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01370642, "Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01370642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*